Evidence map›Paper›PMID 38645223›Full record

ArticlebioRxiv : the preprint server for biology2024

The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1.

Rodrigo Romero, Tinyi Chu, Tania J González-Robles, Perianne Smith, Yubin Xie, Harmanpreet Kaur, Sara Yoder, Huiyong Zhao, Chenyi Mao, Wenfei Kang and 15 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 3 countries.

Rodrigo RomeroHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-9388-8306
Tinyi ChuProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-3369-6692
Tania J González-RoblesInstitute of Systems Genetics, Department of Precision Medicine, NYU Grossman School of Medicine, New York, NY 10061, USA.ORCID 0000-0001-9292-382X
Perianne SmithHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Yubin XieProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-2542-2544
Harmanpreet KaurHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sara YoderDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Huiyong ZhaoAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Chenyi MaoMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Wenfei KangMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Maria V PulinaMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Kayla E LawrenceHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Anuradha GopalanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Samir ZaidiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Kwangmin YooDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
Jungmin ChoiDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
Ning FanMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Olivia GerstnerHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Wouter R KarthausHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-9234-9044
Elisa DeStanchinaAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Kelly V RugglesInstitute of Systems Genetics, Department of Precision Medicine, NYU Grossman School of Medicine, New York, NY 10061, USA.ORCID 0000-0002-0152-0863
Peter M K WestcottCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.ORCID 0000-0001-9436-4857
Ronan ChalignéProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-4332-3291
Dana Pe'erProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-9259-8817
Charles L SawyersHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-4955-6475
Memorial Sloan Kettering Cancer Center · USIndiana University School of MedicineKorea University · KRCold Spring Harbor Laboratory · USKettering University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0M
The Center for Tumor-Immune Systems Biology at MSKCCU54CA274492 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christina S Leslie · 2022 to 2026
$16.3M
Project 3: The Evolving Role of Regional Lymph Nodes in Melanoma ProgressionU54CA263001 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Eva Hernando · 2022 to 2026
$11.6M
The MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2017 to 2021
$6.8M
Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7M
Understanding Resistance to Next Generation AntiandrogensR01CA155169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2012 to 2022
$3.8M
Training Program in Cell BiologyT32GM136542 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SMITH, SUSAN · 2020 to 2024
$3.0M
Translational Research in Oncology Training ProgramT32CA160001 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2011 to 2020
$2.0M
Studies on Lineage Plasticity in Prostate CancerK08CA282978 · NCI · YALE UNIVERSITY · PI SAMIR ZAIDI · 2023 to 2026
$1.1M
Mechanisms and strategies to rescue suboptimal T cell priming in colon cancerK22CA279501 · NCI · COLD SPRING HARBOR LABORATORY · PI WESTCOTT, PETER MAXWELL KIENITZ · 2023 to 2025
$603k
NCI NIH HHS K08 CA282978NCI NIH HHS K22 CA279501NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS R01 CA155169NCI NIH HHS R01 CA193837NCI NIH HHS T32 CA160001NCI NIH HHS U54 CA224079NCI NIH HHS U54 CA263001NCI NIH HHS U54 CA274492NIGMS NIH HHS T32 GM136542
6 · The paper itself

Abstract

Lineage plasticity is a recognized hallmark of cancer progression that can shape therapy outcomes. The underlying cellular and molecular mechanisms mediating lineage plasticity remain poorly understood. Here, we describe a versatile

Identifiers

PMID38645223
PMCPMC11030418
OpenAlexW4394718125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.